Quick Order

DLL4/Delta-like 4 Rabbit MAb

    DatasheetReviewsRelated ProductsProtocols
    Human DLL4 Antibody Product Information
    Immunogen:Recombinant Human DLL4 protein (Catalog#10171-H08H)
    Clone ID:003
    Ig Type:Rabbit IgG
    Concentration:
    Formulation:0.2 μm filtered solution in PBS with 5% trehalose
    Preparation:This antibody was obtained from a rabbit immunized with purified, recombinant Human DLL4 / Delta4 extracellular domain (rh DLL4; Catalog#10171-H08H; NP_061947.1; Met 1-Pro 524).
    Other DLL4 Antibody Products
    Reactivity: Human  
    Application: ELISA  
      10171-MM15-100
      10171-MM15-50
      10171-MM15-200
      100 µg 
      50 µg 
      200 µg 
      Add to Cart
      Reactivity: Human  
      Application: ELISA  
        10171-RP01-100
        10171-RP01-200
        10171-RP01-400
        100 µg 
        200 µg 
         
        Add to Cart
        Reactivity: Human  
        Application: ELISA  
          10171-RP02-50
          10171-RP02-100
          10171-RP02-200
          50 µg 
          100 µg 
          200 µg 
          Add to Cart
          Reactivity: Human  
          Application: ELISA  
            10171-MM06-50
            10171-MM06-100
            10171-MM06-200
            50 µg 
            100 µg 
            200 µg 
            Add to Cart
            Reactivity: Mouse  
            Application: ELISA  
              50640-RP01-100
              50640-RP01-200
              50640-RP01-400
              100 µg 
              200 µg 
               
              Add to Cart
              Reactivity: Mouse  
              Application: ELISA  
                50640-RP02-50
                50640-RP02-100
                50640-RP02-200
                50 µg 
                100 µg 
                200 µg 
                Add to Cart
                Reactivity: Mouse  
                Application: ELISA  
                  50640-R006-50
                  50640-R006-100
                  50 µg 
                  100 µg 
                  Add to Cart
                  DLL4/Delta-like 4 Background

                  Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.

                  Human DLL4/Delta-like 4 References
                • Yan M, et al. (2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 13(24): 7243-6.
                • Sainson RC, et al. (2007) Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med. 13(9): 389-95.
                • Martinez JC, et al. (2009) Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 54(5): 598-606.
                • Li JL, et al. (2010) Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6(7): 1099-103.
                • Product nameProduct name
                  Size / Price
                  Catalog: 10171-R003-1
                  List Price: 
                  Price:      (You Save: )

                  Datasheet & Documentation

                  All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
                  Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"